POLYRIZON LTD Aktie

Polyrizon has finalized agreements with the fourth and fifth clinical centers, thereby contracting all five sites for the first human study of NASARIX (PL-14). The prospective, multicenter, randomized, single‑blind, two‑arm study will treat up to 120 patients with seasonal allergic rhinitis in a 1:1 ratio with either NASARIX or an isotonic saline spray. The primary endpoint is the difference in the average daily reflective total nasal symptom score over the first 14 days of treatment; safety and several secondary efficacy endpoints, as well as contextual data on pollen counts and weather, will also be collected. » Mere på de.investing.com

The European Patent Office has completed the technical preparations to publish Polyrizon’s patent application EP 4751737 for the mucoadhesive "Trap & Target" platform. The technology aims to increase residence time in the nasal cavity and improve drug uptake of intranasally administered medicines. The application now enters the European examination procedure; if granted, it could provide protection in several European markets. » Mere på de.investing.com

Polyrizon has extended the exclusivity period and the initial negotiation phase for the planned acquisition of a 51 percent stake in Arrow Aviation until June 30, 2026. All other terms of the existing letter of intent remain unchanged. The extension builds on the non-binding letter of intent announced in February 2026. » Mere på de.investing.com